Department of Psychiatry, Faculty of Heath Sciences, University of Stellenbosch, Cape Town, South Africa.
Early Interv Psychiatry. 2013 Aug;7(3):247-54. doi: 10.1111/eip.12027. Epub 2013 Jan 24.
There are sound reasons for considering the use of long-acting injectable antipsychotics early in the course of schizophrenia. We reviewed available literature on the subject.
We conducted an electronic database search and critically reviewed all studies in which a long-acting injectable antipsychotic was evaluated in early psychosis patients.
There is a need for well-designed studies as most of those reported were open-label and non-comparative, and samples were frequently small.
The available evidence does suggest that long-acting injectable antipsychotics can be used safely and effectively in early stages of the illness, and that they may be associated with better outcomes than with oral medications. However, this is largely supported by evidence from naturalistic cohort studies and a small number of controlled trials of risperidone long-acting injection. Evidence for olanzapine and paliperidone long-acting injectables in particular is limited.
有充分的理由考虑在精神分裂症病程早期使用长效注射抗精神病药物。我们对相关文献进行了综述。
我们进行了电子数据库检索，并对所有评估早期精神病患者使用长效注射抗精神病药物的研究进行了批判性评价。
需要精心设计的研究，因为大多数已报告的研究为开放标签和非对照研究，样本量通常较小。
现有证据确实表明，长效注射抗精神病药物可在疾病早期安全有效地使用，且与口服药物相比，可能具有更好的疗效。然而，这主要是基于自然队列研究和少数利培酮长效注射的对照试验的证据。奥氮平和帕利哌酮长效注射剂的证据尤其有限。
